Other Deals Are Up 3000% in 2026 — Here's the Data

Thirty deals in six months — up from zero in the prior period — represent a 3,000% surge in transactions classified outside traditional therapeutic-area silos. Comparing the window of 2025-08-27 to 2026-02-27 (zero deals) against 2026-02-27 to 2026-08-27 (30 deals), the other licensing 2026 landscape has gone from dormant to hyperactive. The driver is unmistakable: Big Pharma is hunting beyond conventional drug licensing, acquiring platform technologies, enabling tools, and cross-sector assets that don't fit neatly into oncology, immunology, or cardiovascular buckets — and they're paying premium prices to do it.

The Data — Other Deal Activity, Period over Period

This isn't noise. A jump from zero to 30 signals a structural category emergence, not a statistical blip. The "other" classification itself is instructive — these are deals that taxonomies built around disease areas struggle to capture. Platform biologics, AI-native drug design, reagent and tools businesses, and diagnostic-therapeutic hybrids now constitute a definable, investable deal category. The other deal trends 2026 data makes that case unambiguously.

What's Driving the Trend

Platform hunger has overtaken pipeline hunger. For the past three years, large pharma has absorbed the lesson that individual asset deals carry binary clinical risk, while platform acquisitions offer optionality across multiple programs. The Merck KGaA–Bio-Techne transaction is the defining proof point: an $11.3 billion total deal value for a company whose core business is research reagents, proteins, and instruments — not drug candidates. Merck KGaA isn't buying a molecule. It's buying an infrastructure layer that underpins biologics R&D across the industry. That's a fundamentally different thesis than traditional other licensing 2026 activity would suggest, and it changes the math for every tools-and-platforms company weighing a partnership versus a sale.

Generative AI is creating a new asset class. The Generate: Biomedicines–Novartis deal — announced June 28, 2026 — is a landmark. Novartis didn't license a specific antibody or peptide; it secured access to a generative biology platform capable of designing novel proteins computationally. Terms weren't disclosed, but the strategic intent is clear: Novartis is positioning AI-designed biologics as a core pipeline engine, not a bolt-on. This deal category didn't exist in 2024. By mid-2026, it's pulling marquee partners. BD teams still benchmarking only against traditional licensing comps are using the wrong reference set.

Capital reallocation from late-stage clinical bets to enabling technology is accelerating. The macro backdrop matters. With FDA approval timelines lengthening in several therapeutic areas and CRL activity elevated, pharma CFOs are diversifying spend toward assets with lower binary risk and higher strategic optionality. A $150M upfront to YaoPharma from Pfizer — with $2.05B in total deal value — illustrates that even conventional pharma players are reaching into non-traditional geographies and asset types when the strategic fit is right. Cross-border, cross-category deals are the new normal, and the 30-deal cluster in H1 2026 reflects that portfolio logic at scale. For current Deal Benchmarks across deal types and sizes, the data confirms this diversification pattern.

Notable Deals

The Merck KGaA–Bio-Techne acquisition dominates. At $11.3 billion, this is one of the largest tools-sector transactions in biopharma history. The multiple reporting dates (June 15, 25, and 28) likely reflect the deal's progression from announcement through regulatory filings and closure. The strategic logic: Merck KGaA gains vertical integration across the biologics value chain — from discovery reagents to process development tools — reducing dependency on external suppliers and locking in margin. This is a supply-chain play dressed as an M&A transaction, and it should alarm every mid-cap tools company that hasn't stress-tested its strategic alternatives.

Generate: Biomedicines–Novartis is the bellwether for AI-native deals. Undisclosed financials make direct benchmarking difficult, but the signal is the partnership itself. Novartis validated generative biology as a licensable platform — not an internal R&D curiosity. Every AI-biology company now has a reference deal. Expect valuations for computational biology platforms to reprice upward in the next 12 months. Use Solidus to stress-test how your platform's deal terms compare.

YaoPharma–Pfizer signals geographic diversification. A $150M upfront from Pfizer to a Chinese pharma company, with $2.05B in milestones, reflects Pfizer's willingness to source assets from non-traditional partners when the asset profile justifies it. The upfront-to-TDV ratio (7.3%) is conservative, suggesting significant clinical and regulatory milestones ahead. This deal structure — modest upfront, back-loaded value — will likely become the template for cross-border other licensing 2026 transactions where regulatory uncertainty is elevated.

What This Means for BD Teams Right Now

If you're a platform company, this is a seller's market — but only if you move in the next two quarters. The concentration of deals in June 2026 suggests a wave of competitive tension among large pharma buyers. When Novartis, Merck KGaA, and Pfizer all execute non-traditional deals in the same month, it compresses timelines for every other buyer watching the space. BD teams at platform and tools companies should be running competitive processes now, not waiting for inbound interest.

Deal structures are bifurcating. Outright acquisitions (Bio-Techne at $11.3B) sit at one extreme. Milestone-heavy licensing (YaoPharma at $150M upfront / $2.05B TDV) sits at the other. The middle ground — co-development deals, option-based structures, equity-plus-milestones — is where most of the 30 deals in this category likely cluster. BD teams should benchmark against both extremes and build term sheets that reflect their risk tolerance. The Deal Benchmarks page provides current comps across structure types.

For buyers: the premium window is open but narrowing. Platform assets that were available for $500M–$2B in 2024 are repricing at 3–5x those levels. Bio-Techne's $11.3B tag is an outlier, but it resets the ceiling. If your corporate development team has tools-and-platforms targets on the long list, the cost of waiting another 12 months is quantifiable — and it's significant. Run the scenario analysis on the Ambrosia calculator to see how current market rates apply to your target profile.

Benchmark your deal against current market rates. Whether you're structuring an AI-platform partnership, evaluating a tools acquisition, or negotiating a cross-border license, the data has shifted materially in 2026. Use the Ambrosia calculator to pressure-test your terms against verified deal comps — not last year's assumptions.